mRNA 1011
Alternative Names: mRNA-1011Latest Information Update: 05 Dec 2023
At a glance
- Originator Moderna Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 20 Nov 2023 ModernaTX completes phase I/II trial in Influenza virus infections (Prevention, In adults, In the elderly) in USA (IM) (NCT05827068)
- 27 Mar 2023 Phase-I/II clinical trials in Influenza virus infections (Prevention, In adults, In the elderly) in USA (IM) (NCT05827068)
- 22 Feb 2022 Preclinical trials in Influenza virus infections (Prevention) in USA (unspecified route) (Moderna Therapeutics pipeline, February 2022)